Fast + Reliable Women’s Health Testing Solutions To Meet Your Needs
We understand your patients have varying needs which means you need a diverse set of tools to quickly and effectively test and treat for a range of conditions.
Our high-quality, women’s health rapid antigen tests are made in the U.S.A. and designed to be accurate and easy to use so you can get results fast.
We make diagnostics that matter because we believe each test represents the health and well-being of a real person.
Learn
Getting the most from this guide
1. Scan the QR code next to the product to view additional information, brochures, videos, and more.
2. Go to www.PhysiciansOfficeResource.com and enter the four-digit reference number found next to the product or service into the search field, then request additional information, schedule a demo, or speak with a sales agent all with just a simple click of a button.
3. Find the Business Reply Card in this issue, circle the desired reference numbers, complete the form, and drop into any USPS mailbox. A representative will contact you as quickly as possible to answer your questions.
PUBLISHED BY Medical Education Resources, LLC
PUBLISHER
Aaron R. Medaris amedaris@physiciansofficeresource.com
CEO
Andrew C. Nimmo acnimmo@physiciansofficeresource.com
PRESIDENT
John D. Pasquale jpasquale@pharmaconnect.com
BUSINESS MANAGER
Marci J. Hills mhills@physiciansofficeresource.com
To continue your free subscription of Physicians Office Resource magazine, please fill out the Business Reply Card (BRC) located within this magazine and drop in any United States Post Office mailbox.
If you are a manufacturer of medical products or provide services to medical professionals and would like to advertise your products or services to the nation’s top physicians doing in-office testing, call 801-380-6094 or visit: POR.io for more information.
Buy 2 tests, receive a BD Veritor™ Plus Analyzer at no cost
Invest in Simplicity
Results in 15 minutes or less with a broad portfolio of respiratory assays*
Get ready for respiratory disease season with a flexible analyzer offering tests that include RSV, Strep A, Flu A+B, COVID-19, and a Flu + COVID combo assay.†
Buy any of these combo kits to receive a BD Veritor ™ Plus Analyzer at no cost
BD item number Combo kits
256095 2 BD Veritor ™ System for Rapid Detection of SARS-CoV-2 & Flu A+B † kits
256084 2 BD Veritor ™ System for SARS - CoV - 2 kits
256074 2 BD Veritor ™ System for Rapid Detection of Flu A+B (CLIA-waived) kits
256073 2 BD Veritor ™ System for Rapid Detection of Flu A+B (Moderate Complexity) kits
256080 2 BD Veritor ™ System for Rapid Detection of Group A Strep (CLIA-waived) kits + 1 BD Veritor ™ System for Rapid Detection of Flu A+B (CLIA-waived) kit
256128 2 BD Veritor ™ System Rapid Detection of RSV kits
1 kit = 30 tests
*Result processing times for each BD Veritor™ assay are 15 minutes for the SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays, 10 minutes for Flu A+B and RSV assays, and 5 minutes for the Group A Strep assay.
†For SARS-CoV-2 & FLU A+B: In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Rapid diagnosis, timely care: A case study demonstrating the impact of rapid antigen testing in urgent care
Author: Rajesh Geria MD, Emergency/Urgent Care Physician, CityMD/Summit Health, Envision Health Services
Background
Rapid antigen tests (RATs) are often utilized in urgent care settings due to their ability to provide timely and accurate diagnoses of infectious diseases at the point-of-care. These tools help guide appropriate interventions and improve patient outcomes. This case study highlights how the BD Veritor™ Plus System, a RAT platform, supported real-time clinical decision-making for a pediatric patient presenting with non-specific respiratory symptoms during peak respiratory season at a busy urgent care clinic.
Case Summary
A 7-year-old previously healthy male presented to urgent care during peak respiratory syncytial virus (RSV) season with a 2-day history of fever, body aches, sore throat, and non-productive cough. He had no known sick contacts, and his vaccinations were up to date.
• Physical exam: Mild pharyngeal erythema, clear nasal discharge, postnasal drip, no tonsillar exudates or cervical lymphadenopathy; lungs clear bilaterally.
The differential diagnosis included Influenza, SARS-CoV-2, RSV, pneumonia, and other acute viral infections.
Diagnostic Approach
As per clinic protocol, rapid antigen testing was performed at bedside using the BD Veritor Plus System prior to provider evaluation. The following results were obtained within 15 minutes:*
• Influenza A: Positive • SARS-CoV-2: Negative
• Influenza B: Negative • RSV: Negative
Management and Outcome
Since symptoms began within 48 hours, Oseltamivir was prescribed. Antibiotics were avoided. The patient’s mother received education on supportive care, home isolation, and when to seek follow-up care. She expressed high satisfaction with the rapid diagnosis and the ability to initiate treatment immediately. At follow-up three days later, the child’s symptoms had significantly improved.3
*Result processing times for each BD Veritor™ assay are 15 minutes for the SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays, 10 minutes for Flu A+B and RSV assays, and 5 minutes for the Group A Strep assay.
Discussion
Urgent care centers play a critical role in managing episodic respiratory illnesses. In 2022, nearly 30% of U.S. children were evaluated in an urgent care or retail clinic setting. Clinicians are often faced with patients exhibiting overlapping symptoms from multiple pathogens. These symptoms commonly co-occur in fall and winter, making symptom-based diagnosis challenging and reinforcing the need for accurate diagnostic testing.1
Anecdotally, since the COVID-19 pandemic, patients visiting urgent care clinics seem to have higher expectations for receiving clear answers during their visit. Many now want to know exactly what infection they have during the visit, viral or bacterial, so they can make informed decisions about returning to work or school and avoid spreading illness to friends and family. The days of patients simply accepting, “it’s just a common cold,” appear to be gone. Instead, there is a growing demand for real-time results at the point of care.
Molecular PCR testing became the gold standard during the COVID-19 pandemic due to its sensitivity and public health value. However, PCR presents limitations in urgent care: delayed results, inconsistent reimbursement, and higher costs. As the pandemic phase has transitioned, there’s been a shift toward more accessible and efficient testing methods.2
In this case study, the BD Veritor™ Plus System proved highly beneficial. It offers multiple assay combinations (e.g., SARS-CoV-2 & Flu A+B, Flu A+B, RSV, Group A Strep) relevant to urgent care. These assays provide digitally interpreted results in 15 minutes or less—ideal for urgent care workflows.5
Accuracy High (if early/symptomatic) Very high (all phases)
Use case POC triage, rapid Rx
Confirmatory, late illness
Infection control Helps isolate quickly May delay containment
The BD Veritor™ Plus analyzer is portable, battery-operated, and easy to use in any clinical setting. Its digital result interpretation enhances accuracy. CDC notes that RIDTs using analyzers show higher sensitivity compared to visual reads. ADLM adds that automated result interpretation reduces subjectivity and improves accuracy.
Conclusion
The BD Veritor™ Plus System is a valuable diagnostic tool in urgent care. It supports timely diagnosis, evidence-based management, antibiotic stewardship, improved patient satisfaction, and faster patient throughput—making it ideal for both pediatric and adult urgent care populations.
References:
1. Centers for Disease Control and Prevention. (2024). QuickStats: Percentage of children and adolescents aged ≤17 years who visited an urgent care center or a clinic in a drug store or grocery store in the past 12 months, by age group and year — National Health Interview Survey, United States, 2021–2022. MMWR Morbidity and Mortality Weekly Report, 73(3), 68. https://doi.org/10.15585/mmwr.mm7303a5
2. Centers for Disease Control and Prevention. COVID-19 testing: what you need to know. CDC. Updated March 10, 2025. https://www.cdc.gov/covid/testing/index.html
3. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. CDC. Updated December 8, 2023. https://www.cdc.gov/flu/hcp/antivirals/summaryclinicians.html
4. Centers for Disease Control and Prevention. Interim Guidance for Antigen Testing for SARS-CoV-2. Updated January 20, 2022. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/ antigen-tests-guidelines.html
5. Cooper L, Eckert K, Mann J, et al. Accuracy of an antigen-detecting SARS-CoV-2 assay with self- and provider-collected specimens interpreted visually and with BD Veritor™ Plus analyzer. J Clin Virol Plus. 2023;3(1):100140. doi:10.1016/j.jcvp.2023.100140
Stelo sets the standard in glucose sensing innovation, revolutionizing the path to better long-term wellness.
Stelo by Dexcom’s innovative glucose-sensing technology empowers your patients to take control of their glucose health between office visits with no prescription required.†, 1-4
Reduces practice workload by generating personalized patient tips and insights.1
For Stelo app compatibility information, visit stelo.com/compatibility. *Results obtained from previous Dexcom device(s) in patients with diabetes. †For adults 18 years and older who are not on insulin. 1 Stelo User Guide. 2 Porter, et al. J Diabetes Sci Technol. 2022;16(2):578-580. 3 Ehrhardt, et al. Clin Diab. 2020;38(2):1-6. 4 Clark TL, et al. Diabetes Technol Ther. 2024;26(10):700-8. STELO IMPORTANT
Over 90% of Stelo users build healthier habits, including exercise and nutrition, within three weeks.1 Built-in reporting and 24/7 insights make it easier for patients to review glucose patterns and understand how their habits affect their glucose levels.2
January 13–17, 2026 Chula Vista, CA www.handsurgery.org
American Society for Reconstructive Microsurgery Annual Meeting 2026
January 16–20, 2026 Chula Vista, CA www.microsurg.org
CANS Annual Meeting 2026
California Association of Neurological Surgeons
January 16–19, 2026 Oxnard, CA www.cans1.org
STS Annual Meeting Society of Thoracic Surgeons
January 29 – February 1, 2026
New Orleans, LA www.sts.org
FEBRUARY
Pri-Med South
February 6–8, 2026 Fort Lauderdale, FL www.pri-med.com
Biophysical Society Annual Meeting 2026 Biophysical Society February 21–25, 2026 San Francisco, CA www.biophysics.org/ 2025meeting#/
2026 AAAAI Annual Meeting
American Academy of Allergy Asthma & Immunology
February 27 – March 2, 2026 Philadelphia, PA www.annualmeeting. aaaai.org
MARCH
AAOS Annual Meeting 2026
American Academy of Orthopaedic Surgeons
March 2–6, 2026
New Orleans, LA www.aaos.org
AAPM Annual Meeting
American Academy of Pain Medicine
March 5 – 8
Salt Lake City, UT https://painconnect.org
2026 Annual HIMSS Conference & Exhibition Healthcare Information and Management Systems
March 9–12, 2026
Las Vegas, NV www.himssconference. org
SCCM Critical Care Congress Society of Critical Care Medicine
March 22–24, 2026 Chicago, IL www.sccm.org
AMGA Annual Conference 2026 American Medical Group Association
March 25–28, 2026 Orlando, FL www.amga.org
SAGES 2026 Annual Meeting
Society of American Gastrointestinal Endoscopic Surgeons
March 25–28, 2026 Tampa, FL www.sages2025.org
SSO 2026 Annual Cancer Symposium Society of Surgical Oncology
March 26–28, 2026 Miami Beach, FL www.surgonc.org
ORS 2026 Annual Meeting Orthopaedic Research Society
March 27–31, 2026 Charlotte, NC www.ors.org
AAD Annual Meeting 2026
American Academy of Dermatology
March 27–31, 2026 Denver, CO www.aad.org/meetings/ annual-meeting
AAC 2026 Annual Scientific Session and Expo
American College of Cardiology
March 28–30, 2026 New Orleans, LA https://accscientificsession.acc.org
APRIL
Pri-Med West 2026
April 9 – 11, 2026 Anaheim, CA www.pri-med.com
The Aesthetic Meeting 2026
The American Society for Aesthetic Plastic Surgery
April 9–12, 2026 Las Vegas, NV www.surgery.org
SGO 2026 Annual Meeting on Women’s Cancer Society of Gynecologic Oncologists
April 10–13, 2026 San Juan, PR www.sgo.org
AORN Global Surgical Conference & Expo 2026
Association of Perioperative Registered Nurses April 11 – 14, 2026 New Orleans, LA www.aorn.org
SIR 2026 Annual Scientific Meeting Society of Interventional Radiology
April 11 - 15, 2026 Toronto, ON www.SIRmeeting.org
ACP Internal Medicine Meeting 2026
American College of Physicians
April 16 – 18, 2026 San Francisco, CA https://annualmeeting. acponline.org/
AACR Annual Meeting 2026
American Association of Cancer Research
April 17 – 22, 2026 San Diego, CA www.aacr.org
AAN Annual Meeting
2026
American Academy of Neurology
April 18 – 22, 2026 Chicago, IL www.aan.com
ARRS Annual Meeting 2026
American Roentgen Ray Society
April 12 – 15, 2026 Pittsburgh, PA www.arrs.org
AACE 2026 Annual Scientific & Clinical Congress
American Association of Clinical Endocrinologists
April 22 – 24, 2026 Las Vegas, NV https://am.aace.com
ASBS Annual Meeting 2026
American Society of Breast Surgeons
April 29 – May 3, 2026 Seattle, WA www.breastsurgeons.org
MAY
AANS Annual Scientific Meeting 2026
American Association of Neurological Surgeons
May 1 – 4, 2026 San Antonio, TX www.aans.org
ACOG 2026 Annual Clinical and Scientific Meeting
American College of Obstetricians and Gynecologists
May 1 – 3, 2026 Washington, DC www.acog.org
AATS Annual Meeting 2026
American Association for Thoracic Surgery
TBD May 2 – 5, 2026 Chicago, IL www.aats.org
ACR Annual Meeting 2026
American College of Radiology
May 2 – 6, 2026 Washington, DC www.acr.org/annual-meeting
Pri-Med Southwest 2026
May 6 – 8, 2026 Houston, TX www.pri-med.com
ASLMS 2026 Annual Conference
American Society for Laser Medicine & Surgery
May 7 – 9, 2026 Savannah, GA www.aslms.org
ATS 2026 International Conference
American Thoracic Society
May 17 – 20, 2026 Orlando, FL
ASNR Annual Meeting & The Foundation of the ASNR Symposium 2026 American Society of Neuroradiology
May 17 – 20, 2026 Austin, TX
www.asnr.org
ACSM Annual Meeting
American College of Sports Medicine
May 26 – 29, 2026 Salt Lake City, UT www.acsm.org/annual-meeting/annual-home
SNMMI 2026 Annual Meeting
Society of Nuclear Medicine & Molecular Imaging
May 30 – June 2, 2026 Los Angeles, CA www.snmmi.org
JUNE
AMA Annual Meeting of House of Delegates 2026
American Medical Association
June 5 – 10, 2026 Chicago, IL www.ama-assn.org
ENDO Annual Meeting 2026
The Endocrine Society
June 13 – 16, 2026 Chicago, IL www.endocrine.org
APIC Annual Conference 2026 Association for Professional in Infection Control and Epidemiology
June 15 – 17, 2026 Nashville, TN
BIO International Convention 2026 Biotechnology Industry Organization
June 22 – 25, 2026 San Diego, CA
JULY
AAPM Annual Meeting 2026
American Association of Physicists in Medicine
July 19 – 22, 2026 Vancouver, BC www.aapm.org
ADLM 2026 Annual Meeting & Clinical Lab Expo (Formerly AACC) July 26–30, 2026 Anaheim, CA www.aacc.org
AUGUST
AANA Annual Congress 2026
Arthroscopy Association of North America
August 21 – 25, 2026 Boston, MA www.aana.org
PDA Annual Meeting
Pacific Dermatologic Association
August 21 – 23, 2026 Take Tahoe, CA www.pacificderm.org
SEPTEMBER
ASTRO Annual Meeting 2026
American Society for Therapeutic
September 26 – 30, 2026 Boston, MA www.astro.org
OCTOBER
ACEP Annual Scientific Assembly 2026
American College of Emergency Physicians
October 5 – 8, 2026 Chicago, IL www.acep.org
AAO Annual Meeting
2026
American Academy of Ophthalmology
October 9 – 12, 2026 New Orleans, LA www.aao.org
NASS 2026 Annual Meeting
North American Spine Society
October 14 – 17, 2026 San Antonio, TX www.spine.org
The ANESTHESIOLOGY
2026 Annual Meeting
American Society of Anesthesiologists
October 16 – 20, 2026 San Diego, CA www.asahq.org
CHEST 2026 ACCP Annual Meeting
American College of Chest Physicians
October 18 – 21, 2026 Phoenix, AZ www.chestnet.org
ISPE Annual Meeting 2026
International Society for Pharmaceutical Engineering
October 18 - 21, 2026 Washington, DC www.ispe.org
ASHG 2026
American Society of Human Genetics
October 20 – 24, 2026 Montreal, QC www.ashg.org
FMX 2026
American Academy of Family Physicians
October 20 – 24, 2026 Nashville, TN www.aafp.org
ASRM Scientific Congress and Expo 2026
American Society for Reproductive Medicine
October 24 – 28, 2026 Baltimore, MD www.asrm.org
CNS Annual Meeting 2026
Congress of Neurological Surgeons
October 31 – November 4, 2026 Washington, DC www.cns.org/annualmeeting
NOVEMBER
ACAAI 2026 Annual Meeting
American College of Allergy Asthma & Immunology
November 12 – 16, 2026 Phoenix, AZ www.acaai.org
RSNA 2026
Scientific Assembly and Annual Meeting
November 29 –December 3, 2026 Chicago, IL www.rsna.org
- Move from Waived to Non-Waived Testing with the help of experts
- Expand testing, don’t worry about all the work- policies, fillable forms, e-signatures, calendar reminders included - Remote access – Lab Directors and Consultants manage compliance efficiently, save time, and travel expenses
Schedule a Free Demo Today!
For more information, call 888.534.2977 or email us at
DIAGNOSTIC + DEVICE COMPANY DIRECTORY
A
Abbott
Hematology Division 4551 Great America Parkway Santa Clara CA 95054 408-982-4850 www.corelaboratory. abbott/int/en/offerings/ category/hematology
Abbott Point of Care
400 College Road East Princeton, NJ 08540 800-827-7828 www.globalpointofcare. abbott
Abbott Toxicology
829 Towne Center Dr. Pomona, CA 91767 888-831-6850 https://www.toxicology. abbott
Aerolase
120 White Plains Rd Tarrytown, NY 10591 914-345-8300 www.aerolase.com
ALCOR Scientific Inc. 20 Thurber Blvd Smithfield, RI 02917 800-495-5270 www.alcorscientific.com
Alfa Wassermann 4 Henderson Drive West Caldwell, NJ 07006
800-220-4488 www.alfawassermannus. com
Allscripts 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 800-334-8534 www.allscripts.com
American Academy of Family Physicians 11400 Tomahawk Creek Parkway Leawood, KS 66211-2672 800-274-2237 www.aafp.org
American Screening Corporation
9742 St Vincent Ave. Ste 100 Shreveport, LA 71106 866-526-2873 www.americanscreeningcorp.com
Apyx Medical 5115 Ulmerton Road Clearwater, FL 33760 800-537-2790 www.apyxmedical.com
Arkray 5198 W. 76th Street Edina, MN 55439 800-818-8877 www.arkrayusa.com
B
BD 7 Loveton Circle Sparks, MD 21152 1-800-638-8663 www.bd.com
Beckman Coulter 5350 Lakeview Pkwy S Drive Indianapolis, IN 46268 800-526-3821 www.beckman.com
Bone Index Finland Ltd. 3710 Rawlins St., Suite 1420 Dallas, TX 75219 469-805-5419 www.bindex.us
bioMerieux 1201 S 4800 W Salt Lake City, UT 84104 www.biomerieux.com
Bio-Rad Laboratories 1000 Alfred Nobel Drive Hercules, CA 94547 800-424-6723 www.bio-rad.com
Bionix Development Corporation 1670 Indian Wood Circle Maumee, OH 43537 800-551-7096 www.bionix.com
The Brewer Company N88 W13901 Main Street, Suite 100 Menomonee Falls, WI 53051 888-273-9371 www.brewercompany. com
Patients with Peripheral Artery Disease (PAD) who may be facing a heart attack, stroke, amputation, or even death within the next 5 years
1 O U T O F 3 H A S P A D A N D T H E Y P R O B A B L Y D O N ’ T K N O W I T . A
Diabetics Smokers Over age 65
P E R I P H E R A L
ARTERY DISEASE
Healthy Artery
Diseased Artery
Atherosclerosis
(PAD) is an often silent condition where narrowed arteries reduce blood flow to the legs, causing symptoms like leg pain, numbness, and slow-healing wounds.
DON’T LET PAD SNEAK UP ON YOU OR THESE PATIENTS.
50% report no symptoms, while those that do attribute their pain to arthritis or “old age”.
I N T R O D U C I N G
N o n - i n v a s i v e , p a t i e n t - f r i e n d l y t e s t
A C C U R A T E
A c c u r a c y e q u a l o r b e t t e r t h a n D o p p l e r A B I .
U s e f u l f o r d i a b e t i c s w i t h c a l c i f i e d a r t e r i e s
R E I M B U R S A B L E
r .
G r e a t R O I : t h e t y p i c a l i n t e r n i s t h a s 8 0 0 M e d i c a r e p a t i e n t s , p e r A C P
T
l e s s t h a n t w o m o n t h s .
C P T 9 3 9 2 3 ( A B I w / e x e r
THESE PATIENTS TRUST YOU TO FIND THEIR PAD
before they have a heart attack, stroke, or even die PAD also leads to significant disability and reduced quality of life.
For over 45 years, Newman Medical has been a leader in vascular innovation The ABI-Q system continues that legacy with fast, accurate results you can trust
Comprehensive toxicology menu now with 14 CLIA 1 categorized moderate complexity assays.
IMMTOX ™ 270 BENCHTOP ANALYZER
Toxicology screening solutions for physician offices, pain management, treatment centers and laboratories testing 200+ patient samples/mo.
MODERATE COMPLEXITY ASSAYS – FDA 510(K) CLEARED
6-acetylmorphine (6-AM Heroin metabolite)
Amphetamine
Barbiturates
Benzodiazepines
Benzoylecgonine (Cocaine metabolite)
Buprenorphine
Cannabinoids (THC)
EDDP (Methadone metabolite)
Fentanyl*
Methamphetamine
Opiates
Oxycodone
Phencyclidine (PCP)
Tramadol
Scan this QR code to view the ImmTox™ 270 product video
Real patients. Expert insights.
LIBTAYO patient.
PAD TESTING SYSTEMS IDEAL FOR PRIMARY CARE TO VASCULAR SPECIALISTS
from Newman Medical ABI
Your Patients Trust YOU To Find Their Peripheral Artery Disease
• High-risk patients include those over 65, diabetics, and smokers.
• If left untreated, 25% of patients with PAD will experience a heart attack or stroke within 5 years.
• PAD symptoms are often mistaken for arthritis or old age.
The simpleABI Cuff-Link System is Easy to Learn and Use.
• With a push-button remote, automatic calculations, and waveforms, it’s incredibly user-friendly.
• Reports are straightforward to save and share since the system is PC-based.
Outstanding Value and Reimbursements
• The system pays for itself in less than a year with just one test per week.
• Medicare reimbursements vary by exam and location, averaging from $91 to $174.
BONE HEALTH
WHY BINDEX® IS A GAME-CHANGER IN OSTEOPOROSIS DIAGNOSTICS.
From Bindex Medical
Comparable to DXA
Extensive clinical research has proven Bindex to be 90% accurate in detecting osteoporosis. It can replace nearly 70% of DXA scans for patients with suspected osteoporosis.
Fast and effective
Using safe pulse-echo ultrasound to measure cortical bone thickness, Bindex analyzes bone density in just seconds.
Easy to use anywhere
Lightweight and pocket-sized, Bindex allows patients to receive on-the-spot bone density scans in doctors’ offices, hospitals and clinics and at home.
BRAIN FUNCTION ASSESSMENT
EARLIER DETECTION OF MEMORY LOSS, DEMENTIA AND OTHER COGNITIVE DISORDERS
From Morningside Medical
Standard cognitive screening tools like MMSE/ MOCA are exactly that; screening tools. The technology is there to test the patients that fail these screening tools right in your office. Get clinically relevant information about your patients’ brain performance, while generating additional reimbursement for the practice, leading to earlier diagnosis and more accurate referrals.
Aids in clear diagnosis • Strong Reimbursement • Improves Patient Outcomes
• Easy for any staff to perform • Cognitive Testing / Mental Health • Sudomotor Function / Neuropathy • Vestibular Testing / Fall Prevention • Autonomic Function/ Cardiovascular Risk
5815
5816
CHEMISTRY ANALYZERS
DIAZYME DZ-LITE™ C270 BENCHTOP GENERAL/SPECIAL CHEMISTRIES + DRUG SCREENS
From Carolina Liquid Chemistries
A fully-automated, open system, benchtop clinical chemistry analyzer with throughput up to 270 tests/hour, 36 reagent positions, and 30 sample positions. It features a menu of over 60 CLIA moderate complexity assays, including cancer markers, cardiovascular markers, coagulation markers, diabetic markers, inflammatory markers, liver markers, renal/pancreatic markers, sepsis markers, vitamin markers, photometric electrolytes, and drugs of abuse. To learn more, visit https://www.carolinachemistries.com/products/dz-lite-c270-benchtop-chemistry-analyzer/.
EASYRA® BENCHTOP CHEMISTRIES + DRUGS
From Carolina Liquid Chemistries
When starting a lab, look no further. With a CLIA moderately complex menu of 35 general chemistries and 14 urine drug screens, the EasyRA is well-suited for oncology, rheumatology, and multi-specialty practices needing a benchtop clinical chemistry analyzer. The EasyRA offers photometric throughput of 240+ tests/hr (up to 480 tests/hr with ISE) and STAT samples in under 8 minutes. This all-in-one system is easy to learn and easy to operate.
TOXICOLOGY SCREENING SIMPLIFIED ABBOTT’S IMMTOX
270 BENCHTOP ANALYZER NOW WITH 14 ASSAYS
CLIA CATEGORIZED AS MODERATE COMPLEXITY
From Abbott
The ImmTox270 benchtop analyzer offers comprehensive toxicology screening solutions for physician offices, treatment centers and independent laboratories.
Broad test menu with over 20 assays to choose from including 14 that are now available as moderately complex.
With complete laboratory solutions from consultation to licensure, and compliance the Abbott Clinical Laboratory Solutions team has you covered.
SCAN
NEED MORE CONTROL OVER YOUR POINT-OF-CARE URINALYSIS TESTING PROCESS?
From Siemens Healthineers
CLINITEK Status ® Connect System simplifies wireless or wired connectivity and testing oversight in point-of-care urinalysis for improved risk management.
• Offers flexible connectivity solutions by integrating data directly to the LIS, EMR or via point-of-care data management software solutions
• Provides improved POC testing workflow efficiencies when interfaced to leading data management solutions
• Minimize transcription errors with the 2-D bar-code scanner
• Improves risk management through advanced operator control functions, prevents unauthorized use
• Drives compliance across testing sites with programmable QC protocols and QC lockout
• Auto-Checks* help to ensure the quality and accuracy of data while facilitating an enhanced interpretation of results.
*Only available when using Siemens test strips with IR or color bands
CLIA-WAIVED COMPLETE BLOOD COUNT CITOCBC
From CitoCBC
Cito means “quickly” in Latin, and CitoCBC® brings that efficiency to paitent care. FDA-cleared and CLIA-waived, it delivers lab-quality CBC results in minutes, reporting 16 parameters including a 5-part differential. Its cartridge-based design makes operation simple, while LIS connectivity and monthly QC ensure seamless workflow integration. For urgent care and primary care, CitoCBC is a true differentiator — enabling same-visit diagnostics that elevate patient care.
DRIVE IMPROVED PATIENT OUTCOMES WITH REAL-TIME, ACTIONABLE RESULTS!
From Siemens Healthineers
The DCA Vantage® Analyzer is a multi-parameter, point-of-care analyzer for monitoring glycemic control in patients with diabetes and detecting early kidney disease.
Benefits of the DCA Vantage System:
• CLIA-waived HbA1c test that is IFCC and NGSP-certified
• 1 µl finger stick without fasting – HbA1c results in 6 minutes
• Random urine sample provides A:C ratio in 7 minutes*
• Requires no sample or reagent preparation prior to testing
• Sample integrity safeguards
*CLIA moderately complex.
SCAN
5822
SCAN
5824
OSOM® BVBLUE®
From Sekisui Diagnostics
The OSOM® BVBLUE® detects elevated vaginal fluid sialidase activity, an enzyme produced by bacterial pathogens associated with bacterial vaginosis including Gardnerella, Bacteroides, Prevotella and Mobiluncus. OSOM® BVBLUE® is more sensitive than Amsel criteria providing physicians with a more accurate diagnosis to treat and minimize serious health consequences such as early spontaneous preterm births and miscarriage.
CLIA WAIVED, POINT-OF-CARE, RSV TEST
From Sekisui Diagnostics
Test for both high-risk groups, younger children & elderly adults, for severe RSV infection using the OSOM® RSV Test. This test is a CLIAwaived, point-of-care test designed to detect Respiratory Syncytial Virus (RSV) using a painless anterior nasal swab in just 15 minutes. It is suitable for both children aged 6 months to 6 years and adults aged 60 and above, providing healthcare professionals with flexibility in diagnosing patients exhibiting symptoms of respiratory infections.
OSOM® TRICHOMONAS RAPID TEST
From Sekisui Diagnostics
The OSOM® Trichomonas Rapid Test is intended for the qualitative detection of Trichomonas vaginalis antigens from vaginal swabs or from the saline solution. The OSOM® Trichomonas Rapid Test is a CLIA-waived rapid test available today. OSOM® Trichomonas is more sensitive than wet mount due to the assay being able to detect viable and non-viable organisms which offers significant benefits to the patient and clinician alike.
SCAN TO LEARN MORE
5826
SCAN TO LEARN MORE
5825
SCAN TO LEARN MORE
5827
OSOM ULTRA PLUS FLU A&B TEST
From Sekisui Diagnostics
Stronger Clinical Performance Takes Lateral Flow Testing To The Next Level. Providing superior rapid results at the point-of-care. Fast, easy, cost effective so you can test and treat in one visit.
• High Performance- Equivalent or exceeding the performance of reader devices, without the need for an instrument
• Results in 10 minutes
• OSOM® Custom Care- Exceptional Support/Training by licensed medical technologists and experienced healthcare professionals
• Made in the USA
OSOM®
ULTRA STREP A TEST
From Sekisui Diagnostics
The OSOM® Ultra Strep A test is a color immunochromatographic assay intended for the qualitative detection of Group A Streptococcus antigen directly from throat swab specimens. Shown to be not statistically different than single swab culture. Sensitivity 95.7% and 100% Specificity. Includes two additional test sticks for External QC. CLIA Waived.
COVID-19 OR FLU? STOP GUESSING. ONE SWAB, ONE TEST, RESULTS IN JUST 10 MINUTES
From Sekisui Diagnostics
From only one sample, the OSOM® Flu SARS-CoV-2 Combo Test simultaneously detects and differentiates between COVID-19, Flu A, and Flu B in just 10 minutes, allowing healthcare providers to make more informed decisions when treating patients who are symptomatic with viral infections that have similar symptoms, but different treatment protocols. Designed for point-of-care testing, the OSOM® Flu SARS-CoV-2 Combo Test empowers healthcare providers with the confidence necessary to initiate immediate treatment and isolation protocols at the very first patient visit.
This test has not been FDA cleared or approved. It is authorized by FDA under an EUA for use by authorized laboratories. It has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C S360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
5830
STATUS COVID-19/FLU A&B PANEL TEST
From LifeSign
A Rapid Immunoassay for the Simultaneous Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen from Anterior Nasal and Nasopharyngeal swab specimens. Infections with these viruses may present similar symptoms. Can you tell them apart? WE CAN!
STATUS FLU A&B
From LifeSign
Status Flu A & B is an in vitro rapid qualitative test that detects influenza type A and type B directly from nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens obtained from patients with signs and symptoms of respiratory infection. It is intended to aid in the rapid differential diagnosis of Influenza A and B viral infections.
• CLIA waived *Innovative flip design with onboard sample extraction
• Premeasured developer solution capsule for increased accuracy and ease of use
• Flocked nasal swabs for improved patient comfort and superior specimen collection
ULTRA HCG COMBO TEST
From Sekisui Diagnostics
The OSOM® Ultra hCG Combo test is a simple immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in serum or urine for the early confirmation of pregnancy. Internal studies have confirmed that the OSOM® Ultra hCG Combo test does not have a false negative result from hCG variants providing physicians with a higher level of confidence.
5831
5832
SCAN TO LEARN MORE
5833
COVID-19 TESTING
BIOFIRE SPOTFIRE
From bioMerieux
bioMérieux knows that an evolving world deserves evolved diagnostics. Our latest innovation, the BIOFIRE® SPOTFIRE® Respiratory Solution, is the first FDA-cleared and CLIA-waived COVID-19 testing solution. The BIOFIRE® SPOTFIRE® System is an easy-to-use system that runs the BIOFIRE® SPOTFIRE® Respiratory (R) Panel. Benefits of the SPOTFIRE Respiratory Solution include: 15 respiratory targets on 1 PCR test with results in about 15 minutes; minimal benchtop space with vertical scalability up to four modules; easy to use with an intuitive user interface.
COVID-19 OR FLU? STOP GUESSING. ONE SWAB, ONE TEST, RESULTS IN JUST 10 MINUTES
From Sekisui Diagnostics
From only one sample, the OSOM® Flu SARS-CoV-2 Combo Test simultaneously detects and differentiates between COVID-19, Flu A, and Flu B in just 10 minutes, allowing healthcare providers to make more informed decisions when treating patients who are symptomatic with viral infections that have similar symptoms, but different treatment protocols. Designed for point-of-care testing, the OSOM® Flu SARS-CoV-2 Combo Test empowers healthcare providers with the confidence necessary to initiate immediate treatment and isolation protocols at the very first patient visit.
This test has not been FDA cleared or approved. It is authorized by FDA under an EUA for use by authorized laboratories. It has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C S360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
METRIX® COVID-19 TEST – A MOLECULAR LAB ANYWHERE AND EVERYWHERE
From Sekisui Diagnostics
The Metrix® COVID-19 is a novel technology includes clinical claims for symptomatic and asymptomatic individuals, along with dual-sample types for nasal or saliva, allowing for an enhanced point-of-care testing experience. The reader is compact and robust, it’s ideal for professional use in diverse locations, including clinics and mobile health units. It’s a maintenance free device with no calibration step required.
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA; This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b) (1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
SCAN TO LEARN MORE
5835
SCAN TO LEARN MORE
5836
COVID-19 TESTING
METRIX® COVID/FLU TEST RAPID MOLECULAR TEST – PROVIDE LAB QUALITY RESULTS IN JUST 20 MINUTES
From Sekisui Diagnostics
• 3-in-1 Multiplex – Detects COVID-19, Flu A and Flu B from one swab, in one test
• Minimal Hands-On Time – Can be performed in a CLIA-waived setting in a few simple steps
• Convenient– No maintenance or calibration, ready for testing any time
• Accessible and Flexible – Suitable for any facility
• Exceptional Support – Experienced support teams and online training modules to help streamline your implementation
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA; This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, Influenza A, and Influenza B, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19, Flu A, and Flu B under Section 564(b) (1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
BE PREPARED FOR RESPIRATORY
SEASONS WITH
THE OSOM® COVID-19 ANTIGEN RAPID TEST
From Sekisui Diagnostics
The OSOM® COVID-19 Antigen Rapid Test is a lateral flow immunoassay that detects the SARS-CoV-2 nucleocapsid protein with a nasal swab in only 15 minutes at the point-of-care. The test is intended to be used by healthcare professionals or operators on patients suspected of COVID-19 within the first 7 days of symptom onset. The clinical performance compares favorably against polymerase chain reaction methodology, with a positive percent agreement of 95.1% and a negative percent agreement of 97%.
OSOM® COVID-19 Antigen Rapid Test has not been FDA cleared or approved. It is authorized by FDA under an EUA for prescription use only. It has been authorized only for the detection of SARS-CoV-2 antigen, not for any other viruses or pathogens and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C S360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
SOFIA® 2 FLUORESCENT IMMUNOASSAY ANALYZER AND RAPID DIAGNOSTIC TEST KITS
From QuidelOrtho
Sofia® 2 Fluorescent Immunoassay Analyzer and Rapid Diagnostic Test Kits Sofia 2 takes rapid testing to a new level. Proven lateral-flow technology and advanced fluorescent chemistry are all integrated into this small benchtop analyzer which can be used in any point-of-care setting. Sofia 2 kits are easy to use and adaptable to any healthcare setting. Excellent performance, objectivity, quality control, LIS capabilities, and an expanding test menu make Sofia 2 the perfect solution for the physician’s office laboratory.
SCAN TO LEARN MORE
DIABETES/BLOOD GLUCOSE
NEED MORE CONTROL OVER YOUR POINT-OF-CARE URINALYSIS TESTING PROCESS?
From Siemens Healthineers
CLINITEK Status ® Connect System simplifies wireless or wired connectivity and testing oversight in point-of-care urinalysis for improved risk management.
• Offers flexible connectivity solutions by integrating data directly to the LIS, EMR or via point-of-care data management software solutions
• Provides improved POC testing workflow efficiencies when interfaced to leading data management solutions
• Minimize transcription errors with the 2-D bar-code scanner
• Improves risk management through advanced operator control functions, prevents unauthorized use
• Drives compliance across testing sites with programmable QC protocols and QC lockout
• Auto-Checks* help to ensure the quality and accuracy of data while facilitating an enhanced interpretation of results.
*Only available when using Siemens test strips with IR or color bands
DRIVE IMPROVED PATIENT OUTCOMES WITH REAL-TIME, ACTIONABLE RESULTS!
From Siemens Healthineers
The DCA Vantage® Analyzer is a multi-parameter, point-of-care analyzer for monitoring glycemic control in patients with diabetes and detecting early kidney disease.
Benefits of the DCA Vantage System:
• CLIA-waived HbA1c test that is IFCC and NGSP-certified
• 1 µl finger stick without fasting – HbA1c results in 6 minutes
• Random urine sample provides A:C ratio in 7 minutes*
• Requires no sample or reagent preparation prior to testing
• Sample integrity safeguards
5840
*CLIA moderately complex. 5841
NOVA PRIMARY BLOOD GLUCOSE REFERENCE ANALYZER
From Nova Biomedical
The U.S. FDA has cleared Nova Primary as a blood glucose reference analyzer that fills the need for a new reference analyzer to replace the YSI STAT PLUS 2300 (YSI, Inc., Yellow Springs, OH). Manufacturers of blood glucose measuring devices and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, YSI, Inc. no longer supports the analyzer, and its discontinuation has left a critical industry void. With today’s FDA clearance, Nova Primary from Nova Biomedical is now available in the U.S. and worldwide.
5842
SCAN TO LEARN MORE
FLU AND RESPIRATORY
BD VERITOR™ SYSTEM FOR RAPID DETECTION OF SARS-COV-2 & FLU A+B* (EUA) TEST
From BD Veritor™ Plus System
A 3-in-1 antigen assay for COVID-19, Flu A and Flu B with test results in 15 minutes.1
The BD Veritor™ Plus System streamlines clinical and patient workflows by detecting three key respiratory viruses in one test, reducing the need for multiple sample collections. With multiple testing modes and workflow efficiencies, the analyzer empowers convenience and efficiency (1 kit = 30 tests).
*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
1. BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 and Flu A+B. Package insert. 500051910 Becton, Dickinson and Company.
BIOFIRE SPOTFIRE
From bioMerieux
bioMérieux knows that an evolving world deserves evolved diagnostics. Our latest innovation, the BIOFIRE® SPOTFIRE® Respiratory Solution, is the first FDA-cleared and CLIA-waived COVID-19 testing solution. The BIOFIRE® SPOTFIRE® System is an easyto-use system that runs the BIOFIRE® SPOTFIRE® Respiratory (R) Panel. Benefits of the SPOTFIRE Respiratory Solution include: 15 respiratory targets on 1 PCR test with results in about 15 minutes; minimal benchtop space with vertical scalability up to four modules; easy to use with an intuitive user interface.
COVID-19 OR FLU? STOP GUESSING. ONE SWAB, ONE TEST, RESULTS IN JUST 10 MINUTES
From Sekisui Diagnostics
From only one sample, the OSOM® Flu SARS-CoV-2 Combo Test simultaneously detects and differentiates between COVID-19, Flu A, and Flu B in just 10 minutes, allowing healthcare providers to make more informed decisions when treating patients who are symptomatic with viral infections that have similar symptoms, but different treatment protocols. Designed for point-of-care testing, the OSOM® Flu SARS-CoV-2 Combo Test empowers healthcare providers with the confidence necessary to initiate immediate treatment and isolation protocols at the very first patient visit.
This test has not been FDA cleared or approved. It is authorized by FDA under an EUA for use by authorized laboratories. It has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C S360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
5844
SCAN
FLU AND RESPIRATORY
METRIX® COVID-19 TEST –
A
MOLECULAR LAB ANYWHERE AND EVERYWHERE
From Sekisui Diagnostics
The Metrix® COVID-19 is a novel technology includes clinical claims for symptomatic and asymptomatic individuals, along with dual-sample types for nasal or saliva, allowing for an enhanced point-of-care testing experience. The reader is compact and robust, it’s ideal for professional use in diverse locations, including clinics and mobile health units. It’s a maintenance free device with no calibration step required.
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA; This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b) (1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
METRIX® COVID/FLU TEST RAPID MOLECULAR TEST – PROVIDE LAB QUALITY RESULTS IN JUST 20 MINUTES
From Sekisui Diagnostics
• 3-in-1 Multiplex – Detects COVID-19, Flu A and Flu B from one swab, in one test
• Minimal Hands-On Time – Can be performed in a CLIA-waived setting in a few simple steps
• Convenient– No maintenance or calibration, ready for testing any time
• Accessible and Flexible – Suitable for any facility
• Exceptional Support – Experienced support teams and online training modules to help streamline your implementation
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA; This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, Influenza A, and Influenza B, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19, Flu A, and Flu B under Section 564(b) (1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
BE PREPARED FOR RESPIRATORY SEASONS WITH THE OSOM® COVID-19 ANTIGEN RAPID TEST
From Sekisui Diagnostics
The OSOM® COVID-19 Antigen Rapid Test is a lateral flow immunoassay that detects the SARS-CoV-2 nucleocapsid protein with a nasal swab in only 15 minutes at the point-of-care. The test is intended to be used by healthcare professionals or operators on patients suspected of COVID-19 within the first 7 days of symptom onset. The clinical performance compares favorably against polymerase chain reaction methodology, with a positive percent agreement of 95.1% and a negative percent agreement of 97%.
OSOM® COVID-19 Antigen Rapid Test has not been FDA cleared or approved. It is authorized by FDA under an EUA for prescription use only. It has been authorized only for the detection of SARS-CoV-2 antigen, not for any other viruses or pathogens and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C S360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
SCAN TO LEARN MORE
SCAN TO LEARN MORE
5847
FLU AND RESPIRATORY
CLIA WAIVED, POINT-OF-CARE, RSV TEST
from Sekisui Diagnostics
Test for both high-risk groups, younger children & elderly adults, for severe RSV infection using the OSOM® RSV Test. This test is a CLIAwaived, point-of-care test designed to detect Respiratory Syncytial Virus (RSV) using a painless anterior nasal swab in just 15 minutes. It is suitable for both children aged 6 months to 6 years and adults aged 60 and above, providing healthcare professionals with flexibility in diagnosing patients exhibiting symptoms of respiratory infections.
OSOM ULTRA PLUS FLU A&B TEST
From Sekisui Diagnostics
Stronger Clinical Performance Takes Lateral Flow Testing To The Next Level. Providing superior rapid results at the point-of-care. Fast, easy, cost effective so you can test and treat in one visit.
• High Performance- Equivalent or exceeding the performance of reader devices, without the need for an instrument
• Results in 10 minutes
• OSOM® Custom Care- Exceptional Support/Training by licensed medical technologists and experienced healthcare professionals
• Made in the USA
SOFIA® 2 FLUORESCENT IMMUNOASSAY ANALYZER AND RAPID DIAGNOSTIC TEST KITS
From QuidelOrtho
Sofia® 2 Fluorescent Immunoassay Analyzer and Rapid Diagnostic Test Kits Sofia 2 takes rapid testing to a new level. Proven lateral-flow technology and advanced fluorescent chemistry are all integrated into this small benchtop analyzer which can be used in any point-of-care setting. Sofia 2 kits are easy to use and adaptable to any healthcare setting. Excellent performance, objectivity, quality control, LIS capabilities, and an expanding test menu make Sofia 2 the perfect solution for the physician’s office laboratory.
SCAN TO LEARN MORE
5850
SCAN TO LEARN MORE
SCAN TO LEARN MORE
FLU AND RESPIRATORY
STATUS COVID-19/FLU A&B PANEL TEST
From LifeSign
A Rapid Immunoassay for the Simultaneous Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen from Anterior Nasal and Nasopharyngeal swab specimens. Infections with these viruses may present similar symptoms. Can you tell them apart? WE CAN!
STATUS FLU A&B
From LifeSign
Status Flu A & B is an in vitro rapid qualitative test that detects influenza type A and type B directly from nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens obtained from patients with signs and symptoms of respiratory infection. It is intended to aid in the rapid differential diagnosis of Influenza A and B viral infections.
• CLIA waived *Innovative flip design with onboard sample extraction
• Premeasured developer solution capsule for increased accuracy and ease of use
• Flocked nasal swabs for improved patient comfort and superior specimen collection
HEMATOLOGY
CELL-DYN
From Abbott
EMERALD
22 HEMATOLOGY ANALYZER
The CELL-DYN Emerald 22 is a full performance 5-part hematology analyzer for smaller clinical laboratories seeking productivity in smaller spaces.
Benefits:
• Compact Design - To conserve valuable workspace.
• Small and Powerful - Includes a numeric keypad entry, reagent tray, and integrated color touchscreen monitor.
• Easy and Automated - Barcoded reagents and touch-free scheduled daily maintenance, startup and shutdown.
• Online product training - Self-pace training available 24x7 on the Abbott’s Hematology Academy.
SCAN TO LEARN MORE
5852
SCAN TO LEARN MORE
5853
SCAN TO LEARN MORE
5854
HEMATOLOGY
TURN SMALL PLACES INTO SMART SPACES
From Abbott
With reduced budgets, shrinking laboratory space and staffing challenges, many laboratories need a solution that lets them work smarter with less. The CELL-DYN Emerald 22 AL is a full performance, automated optical 5-part differential analyzer that delivers smarter results for small to midsize clinical laboratories.
• Compact Design
• Walkaway Functionality
• Ease Of Use
• Smart Safety Features
CLIA-WAIVED COMPLETE BLOOD COUNT CITOCBC
From CitoCBC
Cito means “quickly” in Latin, and CitoCBC® brings that efficiency to paitent care. FDA-cleared and CLIA-waived, it delivers lab-quality CBC results in minutes, reporting 16 parameters including a 5-part differential. Its cartridge-based design makes operation simple, while LIS connectivity and monthly QC ensure seamless workflow integration. For urgent care and primary care, CitoCBC is a true differentiator — enabling same-visit diagnostics that elevate patient care.
PENTRA XLR HEMATOLOGY ANALYZER WITH 5-PART DIFFERENTIAL
From HORIBA Medical
The Pentra XLR hematology analyzer with autoloader provides a CBC with 5-part Diff result using proprietary technology that ensures an accurate count and differential on the first run. The Pentra XLR also provides a complete menu of Retic parameters for treating oncology and anemia patients. The autoloader processes 80 samples an hour and provides random continuous access for medium-to high-volume clinics and rural or community hospitals.
5855
5857
HEMATOLOGY
HEMATOLOGY TESTING MADE EASY
From Sysmex
Designed for labs testing up to 25 samples per day, the Sysmex pocH-100i™ has the smallest footprint of any analyzer on the market. The instrument requires only 15uL of whole blood for reporting of 17 clinical parameters, including a 3-part WBC Differential. It is ideal for urgent care, physician office lab, small clinic, or any outpatient setting where a point of care CBC is needed.
NOW IT’S MORE THANK JUST A BLOOD TEST
From Sysmex
With its simplified operation, the Sysmex XP-300™ is ideal for clinics and physician office labs. It provides a CBC with 17 different parameters, including a 3-part WBC Differential. The XP-300+M combines the accuracy and reliability of a Sysmex CBC with the agility of Medicus Middleware. Features include EMR connectivity, instrument interfaces and a QC module.
LABORATORY SERVICES
MEDICUS LIS
From Medicus LIS
If you are considering in-house lab testing, including Covid-19 testing and required reporting to state agencies, connecting Lab to LIS and EHR makes the process of test orders to completed results much easier. Providers receive test results posted to patient charts in real-time, expediting patient care, saving time, money and even preparing for lab test reimbursement goals. Link Your Lab with Medicus LIS today! Contact us: 888-643-8081 sales@medicuslis.com
5858
5859
SCAN TO LEARN MORE
5860
LABORATORY SERVICES
CLIA COMPLIANT, USER-FRIENDLY, COST-EFFECTIVE, ELECTRONIC DOCUMENTATION SYSTEM
From MyInspection
• Meets all CLIA compliance requirements
• No interpretation of CLIA regulations required – includes all policies, procedures, electronic fillable forms stored systematically for easy retrieval
• Remote access – manage individual or multiple labs remotely from your PC, tablet or phone
• Easy to audit and document changes with electronic signatures and dating
• Expert guidance from licensure to your customized documentation system
• Be, stay compliant and inspection ready – reduce time, cost, and stress
MULTIPLEX TESTING
BIOFIRE SPOTFIRE
From bioMerieux
bioMérieux knows that an evolving world deserves evolved diagnostics. Our latest innovation, the BIOFIRE® SPOTFIRE® Respiratory Solution, is the first FDA-cleared and CLIA-waived COVID-19 testing solution. The BIOFIRE® SPOTFIRE® System is an easy-to-use system that runs the BIOFIRE® SPOTFIRE® Respiratory (R) Panel. Benefits of the SPOTFIRE Respiratory Solution include: 15 respiratory targets on 1 PCR test with results in about 15 minutes; minimal benchtop space with vertical scalability up to four modules; easy to use with an intuitive user interface.
COVID-19 OR FLU? STOP GUESSING. ONE SWAB, ONE TEST, RESULTS IN JUST 10 MINUTES
From Sekisui Diagnostics
From only one sample, the OSOM® Flu SARS-CoV-2 Combo Test simultaneously detects and differentiates between COVID-19, Flu A, and Flu B in just 10 minutes, allowing healthcare providers to make more informed decisions when treating patients who are symptomatic with viral infections that have similar symptoms, but different treatment protocols. Designed for point-of-care testing, the OSOM® Flu SARS-CoV-2 Combo Test empowers healthcare providers with the confidence necessary to initiate immediate treatment and isolation protocols at the very first patient visit.
5862
SCAN TO LEARN MORE
5863
MULTIPLEX TESTING
METRIX® COVID/FLU TEST RAPID MOLECULAR TEST – PROVIDE LAB QUALITY RESULTS IN JUST 20 MINUTES
From Sekisui Diagnostics
• 3-in-1 Multiplex – Detects COVID-19, Flu A and Flu B from one swab, in one test
• Minimal Hands-On Time – Can be performed in a CLIA-waived setting in a few simple steps
• Convenient– No maintenance or calibration, ready for testing any time
• Accessible and Flexible – Suitable for any facility
• Exceptional Support – Experienced support teams and online training modules to help streamline your implementation
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA; This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, Influenza A, and Influenza B, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19, Flu A, and Flu B under Section 564(b) (1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
BD VERITOR™ SYSTEM FOR RAPID DETECTION OF SARS-COV-2 & FLU A+B* (EUA) TEST
From BD Veritor™ Plus System
A 3-in-1 antigen assay for COVID-19, Flu A and Flu B with test results in 15 minutes.1
The BD Veritor™ Plus System streamlines clinical and patient workflows by detecting three key respiratory viruses in one test, reducing the need for multiple sample collections. With multiple testing modes and workflow efficiencies, the analyzer empowers convenience and efficiency (1 kit = 30 tests).
*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
1. BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 and Flu A+B. Package insert. 500051910 Becton, Dickinson and Company.
STATUS COVID-19/FLU A&B PANEL TEST
From LifeSign
A Rapid Immunoassay for the Simultaneous Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen from Anterior Nasal and Nasopharyngeal swab specimens. Infections with these viruses may present similar symptoms. Can you tell them apart? WE CAN!
SCAN TO LEARN MORE
5866
SCAN TO LEARN MORE
PERIPHERAL ARTERIAL DISEASE
QUANTAFLO® PAD
From Semler Scientific
QuantaFlo® PAD is an easy to use, accurate, point of care, non-invasive solution that aids in the early detection of peripheral arterial disease (PAD). This FDA cleared device can be administered by a medical aide in less than 5 minutes. As published in the Journal of Vascular Surgery and the American Journal of Preventive Medicine, QuantaFlo detected undiagnosed PAD in 31.6% of patients +65.1 QuantaFlo is portable and integrates with other technologies and platforms. It is ideal for both home and clinic environments.
1. Smolderen KG, Ameli O, Chaisson CE, Heath K, Mena-Hurtado C. Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events, AJPM Focus (2022), https://doi.org/10.1016/j.focus.2022.100016
PAD TESTING SYSTEMS IDEAL FOR PRIMARY CARE TO VASCULAR SPECIALISTS
from Newman Medical
Your Patients Trust YOU To Find Their Peripheral Artery Disease
• High-risk patients include those over 65, diabetics, and smokers.
• If left untreated, 25% of patients with PAD will experience a heart attack or stroke within 5 years.
• PAD symptoms are often mistaken for arthritis or old age.
The simpleABI Cuff-Link System is Easy to Learn and Use.
• With a push-button remote, automatic calculations, and waveforms, it’s incredibly user-friendly.
• Reports are straightforward to save and share since the system is PC-based. Outstanding Value and Reimbursements
• The system pays for itself in less than a year with just one test per week.
• Medicare reimbursements vary by exam and location, averaging from $91 to $174.
STREP TESTS
OSOM® ULTRA STREP A TEST
From Sekisui Diagnostics
The OSOM® Ultra Strep A test is a color immunochromatographic assay intended for the qualitative detection of Group A Streptococcus antigen directly from throat swab specimens. Shown to be not statistically different than single swab culture. Sensitivity 95.7% and 100% Specificity. Includes two additional test sticks for External QC. CLIA Waived.
STREP TESTS
SOFIA®
2 FLUORESCENT IMMUNOASSAY ANALYZER AND RAPID DIAGNOSTIC TEST KITS
From QuidelOrtho
Sofia® 2 Fluorescent Immunoassay Analyzer and Rapid Diagnostic Test Kits Sofia 2 takes rapid testing to a new level. Proven lateral-flow technology and advanced fluorescent chemistry are all integrated into this small benchtop analyzer which can be used in any point-of-care setting. Sofia 2 kits are easy to use and adaptable to any healthcare setting. Excellent performance, objectivity, quality control, LIS capabilities, and an expanding test menu make Sofia 2 the perfect solution for the physician’s office laboratory.
TOXICOLOGY
TOXICOLOGY SCREENING SIMPLIFIED
ABBOTT’S
IMMTOX 270 BENCHTOP ANALYZER NOW WITH 14 ASSAYS CLIA CATEGORIZED AS MODERATE COMPLEXITY
From Abbott
The ImmTox270 benchtop analyzer offers comprehensive toxicology screening solutions for physician offices, treatment centers and independent laboratories.
Broad test menu with over 20 assays to choose from including 14 that are now available as moderately complex.
With complete laboratory solutions from consultation to licensure, and compliance the Abbott Clinical Laboratory Solutions team has you covered.
TOXICOLOGY URINE DRUG SCREENING REAGENTS
From Abbott
Prescription drug misuse and illicit drug abuse is a growing public health challenge in this country. Building a test profile that covers highly misused drugs has never been so vital. With over 20 relevant assays to choose from Abbott’s suite of Immunalysis reagents allows you to easily screen for relevant substances. Our complete line of assays, calibrators, and controls enables you to implement an efficient drug screening program in office.
SCAN TO LEARN MORE
TOXICOLOGY
FIRST EVER FDA-CLEARED
AND CATEGORIZED, POINT-OF-CARE FENTANYL TEST (<6 MINUTES)
From Carolina Liquid Chemistries
Carolina Liquid Chemistries Corp. introduces the Fentanyl Urine Detection Test on CLC’s next-generation RYAN™ immunofluorescent analyzer. This FDA cleared and CLIA categorized, moderately complex, compact, point-of-care system detects fentanyl qualitatively in human urine at a cutoff concentration of 1.0 ng/mL. The test can be run in < 6 minutes, produces a chartable result, and is interfaceable. For detailed information, visit carolinachemistries.com/products/fentanyl-urinedetect-on-clc-ryan-analyzer/.
The Ethos Automated Ultrasound Probe Cleaner Disinfector is the first FDA-cleared device to provide both cleaning and high-level disinfection of ultrasound probes in one system. It’s fast and easy to use—simply place a soiled transvaginal, transrectal, or surface probe into the device, follow the prompts on the display, and a reprocessing report is printed at the end of the cycle. Ethos removes the unknowns of manual cleaning, giving healthcare professionals confidence and consistency with every cycle.
URINALYSIS
NEED MORE CONTROL OVER YOUR POINT-OF-CARE URINALYSIS TESTING PROCESS?
From Siemens Healthineers
CLINITEK Status ® Connect System simplifies wireless or wired connectivity and testing oversight in point-of-care urinalysis for improved risk management.
• Offers flexible connectivity solutions by integrating data directly to the LIS, EMR or via point-of-care data management software solutions
• Provides improved POC testing workflow efficiencies when interfaced to leading data management solutions
• Minimize transcription errors with the 2-D bar-code scanner
• Improves risk management through advanced operator control functions, prevents unauthorized use
• Drives compliance across testing sites with programmable QC protocols and QC lockout
• Auto-Checks* help to ensure the quality and accuracy of data while facilitating an enhanced interpretation of results.
*Only available when using Siemens test strips with IR or color bands
The Ethos Automated Ultrasound Probe Cleaner Disinfector is the first FDA-cleared device to provide both cleaning and high-level disinfection of ultrasound probes in one system. It’s fast and easy to use—simply place a soiled transvaginal, transrectal, or surface probe into the device, follow the prompts on the display, and a reprocessing report is printed at the end of the cycle. Ethos removes the unknowns of manual cleaning, giving healthcare professionals confidence and consistency with every cycle.
WHY BINDEX® IS A GAME-CHANGER IN OSTEOPOROSIS DIAGNOSTICS.
From Bindex Medical
Comparable to DXA
Extensive clinical research has proven Bindex to be 90% accurate in detecting osteoporosis. It can replace nearly 70% of DXA scans for patients with suspected osteoporosis.
Fast and effective
Using safe pulse-echo ultrasound to measure cortical bone thickness, Bindex analyzes bone density in just seconds.
Easy to use anywhere
Lightweight and pocket-sized, Bindex allows patients to receive on-the-spot bone density scans in doctors’ offices, hospitals and clinics and at home.
OSOM® BVBLUE®
From Sekisui Diagnostics
The OSOM® BVBLUE® detects elevated vaginal fluid sialidase activity, an enzyme produced by bacterial pathogens associated with bacterial vaginosis including Gardnerella, Bacteroides, Prevotella and Mobiluncus. OSOM® BVBLUE® is more sensitive than Amsel criteria providing physicians with a more accurate diagnosis to treat and minimize serious health consequences such as early spontaneous preterm births and miscarriage.
SCAN
SCAN
5878
OSOM® TRICHOMONAS RAPID TEST
From Sekisui Diagnostics
The OSOM® Trichomonas Rapid Test is intended for the qualitative detection of Trichomonas vaginalis antigens from vaginal swabs or from the saline solution. The OSOM® Trichomonas Rapid Test is a CLIA-waived rapid test available today. OSOM® Trichomonas is more sensitive than wet mount due to the assay being able to detect viable and non-viable organisms which offers significant benefits to the patient and clinician alike.
ULTRA HCG COMBO TEST
From Sekisui Diagnostics
The OSOM® Ultra hCG Combo test is a simple immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in serum or urine for the early confirmation of pregnancy. Internal studies have confirmed that the OSOM® Ultra hCG Combo test does not have a false negative result from hCG variants providing physicians with a higher level of confidence.
NEED MORE CONTROL OVER YOUR POINT-OF-CARE URINALYSIS TESTING PROCESS?
From Siemens Healthineers
CLINITEK Status ® Connect System simplifies wireless or wired connectivity and testing oversight in point-of-care urinalysis for improved risk management.
• Offers flexible connectivity solutions by integrating data directly to the LIS, EMR or via point-of-care data management software solutions
• Provides improved POC testing workflow efficiencies when interfaced to leading data management solutions
• Minimize transcription errors with the 2-D bar-code scanner
• Improves risk management through advanced operator control functions, prevents unauthorized use
• Drives compliance across testing sites with programmable QC protocols and QC lockout
• Auto-Checks* help to ensure the quality and accuracy of data while facilitating an enhanced interpretation of results.
*Only available when using Siemens test strips with IR or color bands
SCAN
9 Travel Destinations You Can't Miss in 2026
Whether you're craving pristine beaches or vibrant cities, these nine must-visit destinations around the world promise stunning scenery, rich culture, and unforgettable adventures for every type of traveler.
md-escapes.com
St. Thomas Ritz-Carlton Vienna
Four Seasons Orlando at Walt Disney World
Secret Bay Dominica · Garza Blanca Puerto Vallarta
Four Seasons Napa Valley · Four Seasons Las Vegas
Four Seasons Nashville
Four Seasons Gresham Palace, Budapest
RITZ-CARLTON ST. THOMAS
Escape to an island oasis surrounded by crystal blue waters, white sand and lush tropical greenery. A breathtaking 30 acre, oceanfront luxury hotel in St. Thomas, VI, The Ritz-Carlton, St. Thomas is a Caribbean marvel styled after traditional island architecture, but richly updated with all of the contemporary comforts for which the resorts of The Ritz-Carlton are known.
SCAN TO LEARN MORE
In a city renowned for its beauty and culture, The Ritz-Carlton, Vienna distinguishes itself with a unique blend of modern luxuries, fine dining, and spa experiences, all housed within four 19th-century palaces. Situated in the heart of downtown Vienna, along the iconic Ringstrasse and adjacent to the Stadtpark, our luxury hotel offers 200 elegant guestrooms, including 43 exquisite suites, allowing you to indulge in tasteful living, distinctive designs, and breathtaking views.
SCAN TO LEARN MORE
THE RITZ-CARLTON VIENNA
RITZ-CARLTON ST. THOMAS
THE RITZ-CARLTON VIENNA
FOUR SEASON ORLANDO AT WALT DISNEY WORLD
ORLANDO, FLORIDA
Discover an elevated escape with the perfect balance of fun and relaxation at our AAA Five Diamond, luxury Orlando Resort. Splash around with the family at Explorer Island water park, or unwind beneath swaying palms at Oasis adult-only pool while we entertain your young ones at our complimentary kids camp. Treat yourself to a soothing, post-park massage at The Spa, then toast to the nightly Walt Disney World® fireworks views over dinner at our Michelin-starred rooftop steakhouse Capa.
SCAN TO LEARN MORE
SECRET BAY DOMINICA
Spectacularly sited on a clifftop promontory where the rainforest meets the sea on Dominica, the “Nature Island” of the Caribbean, Secret Bay is among the leading boutique resorts in the world and an acclaimed Relais & Châteaux property. The secluded six-star, all-villa resort consists of elegantly appointed, residential-style villas, each with a private plunge pool and dedicated villa host, on-call concierge, chefs and guides, access to a secret beach and transformative experiences curated specifically for each guest.
SCAN TO LEARN MORE
FOUR SEASONS ORLANDO AT WALT DISNEY WORLD
GARZA BLANCA
PUERTO VALLARTA
All Inclusive Family Resort in Puerto Vallarta. Experience the best all-inclusive resort in Puerto Vallarta, where first-class amenities invite you to relax by infinity pools, indulge in gourmet dining, and rejuvenate at a world-class spa embraced by jungle and ocean views. Garza Blanca Puerto Vallarta combines breathtaking natural beauty, exceptional service, and upscale comfort for an unforgettable luxury family vacation.
SCAN TO LEARN MORE
FOUR SEASONS NAPA VALLEY
Welcome to Five-Star Luxury in California Wine Country. In the food and wine capital of North America, Four Seasons welcomes you to a bespoke luxury resort in Napa Valley, the heart of California wine country. Our Forbes FiveStar Hotel in Calistoga is set within its own world-class vineyard. Discover innovative and seasonal cuisine at Michelin-starred Auro, holistic spa rituals at Spa Talisa and thoughtfully personalized Four Seasons service. Raise a glass to all the best in life as you soak in magnificent views of Napa Valley.
SCAN TO LEARN MORE
GARZA BLANCA
PUERTO VALLARTA
FOUR SEASONS
LAS VEGAS, NEVADA
As one of the only non-gaming and non-smoking hotels on The Strip, Four Seasons Hotel Las Vegas is a unique oasis in the heart of the action-packed sports and entertainment capital of the world. Offering Five Diamond luxury accommodations, acclaimed dining and a Forbes Five-Star spa, Four Seasons offers the best of both worlds: a resort retreat amid the famous energy of Las Vegas.
SCAN TO LEARN MORE
FOUR SEASONS NASHVILLE, TENNESSEE
Welcome to Four Seasons Hotel Nashville, a luxury hotel located in the heart of downtown’s vibrant SoBro neighborhood. This new social hub is just steps away from the city's iconic music, sports, and entertainment venues. Experience the rhythm of our lively restaurants and event spaces, the tranquility of our Spa, and the stunning views from our rooftop pool overlooking the Cumberland River and Riverfront Park. With the unmatched service of Four Seasons and warm Southern hospitality, we’ll inspire an authentic experience of Music City.
SCAN TO LEARN MORE
FOUR SEASONS GRESHAM PALACE BUDAPEST
Located in the heart of Budapest, our luxury art nouveau palace Hotel – the only Forbes Five-Star hotel in Hungary – embodies the spirit of Budapest’s Golden Era glam. From the moment you enter the iconic wrought iron peacock gates, pass through the lobby adorned with more than two million mosaic tiles illuminated with its striking chandelier, and let inspiration wash over you. Outside, views of the Danube and the picturesque Buda skyline stand before you. Spend the day exploring the sights, recharge in our Spa that harnesses the city’s heritage in wellness, then enjoy an innovative cocktail at our lobby bar MÚZSA.
SCAN TO LEARN MORE
Fast + Accurate Point-of-Care Respiratory Solutions To Meet Your Needs
During respiratory season, your patients depend on you to provide fast, accurate diagnosis and effective treatment plans. Having the right diagnostic solutions in your office can help you provide the care your patients expect.
Our product portfolio includes high-quality, point-of-care molecular and antigen tests for diagnosing respiratory illnesses. Our solutions can help you deliver answers and treatment plans for your patients which can get them on the road to recovery and improve outcomes for your clinical practice.
We make diagnostics that matter because we believe each test represents the health and well-being of a real person.